Background: The Centers for Disease Control and Prevention’s National Healthcare Safety Network (NHSN) has included surveillance of laboratory-identified (LabID) methicillin-resistant Staphylococcus aureus (MRSA) bacteremia events since 2009. In 2013, the Centers for Medicare & Medicaid Services (CMS) began requiring acute-care hospitals (ACHs) that participate in the CMS Inpatient Quality Reporting program to report MRSA LabID events to the NHSN and, in 2015, ACHs were required to report MRSA LabID events from emergency departments (EDs) and/or 24-hour observation locations. Prior studies observed a decline in hospital-onset MRSA (HO-MRSA) rates in national studies over shorter periods or other surveillance systems. In this analysis, we review the national reporting trend for HO-MRSA bacteremia LabID events, 2010–2018. Method: This analysis was limited to MRSA bacteremia LabID event data reported by ACHs that follow NHSN surveillance protocols. The data were restricted to events reported for overall inpatient facility-wide and, if applicable, EDs and 24-hour observation locations. MRSA events were classified as HO (collected >3 days after admission) or inpatient or outpatient community onset (CO, collected ≤3 days after admission). An interrupted time series random-effects generalized linear model was used to examine the relationship between HO-MRSA incidence rates (per 1,000 patient days) and time (year) while controlling for potential risk factors as fixed effects. The following potential risk factors were evaluated: facility’s annual survey data (facility type, medical affiliation, length of facility stay, number of beds, and number of intensive care unit beds) and quarterly summary data (inpatient and outpatient CO prevalence rates). Result: The number of reporting ACHs increased during this period, from 473 in 2010 to 3,651 in 2018. The crude HO-MRSA incidence rates (per 1,000 patient days) have declined over time, from a high of 0.067 in 2011 to 0.052 in 2018 (Table 1). Compared to 2014, the adjusted annual incidence rate increased in 2015 by 16.38%, (95% confidence interval [CI], 10.26%–22.84%; P < .0001). After controlling for all significant risk factors, the estimated annual HO-MRSA incidence rates declined by 5.98% (95% CI, 5.17%–6.78%; P < .0001) (Table 2). Conclusions: HO-MRSA bacteremia incidence rates have decreased over the past 9 years, despite a slight increase in 2015. This national trend analysis reviewed a longer period while analyzing potential risk factors. The decline in HO-MRSA incidence rates has been gradual; however, given the current trend, it is not likely to meet the Healthy People 2020 objectives. This analysis suggests the need for hospitals to continue and/or enhance HO-MRSA infection prevention efforts to reduce rates further.
Funding: None
Disclosures: None